Stay updated on Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.

Latest updates to the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page
- Check3 days agoChange DetectedAdded 'B-cell chronic lymphocytic leukemia' as a disease keyword on the Study Details page.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedRevision tag updated to v3.5.0, replacing the previous v3.4.3. No visible changes to study details or page layout.SummaryDifference0.1%

- Check25 days agoChange DetectedFooter revision label updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check39 days agoChange Detected- No visible content changes between the two screenshots. The page content and structure appear identical.SummaryDifference0.1%

- Check53 days agoChange DetectedRevision: v3.4.2 was implemented and the government operating-status notice was removed.SummaryDifference0.4%

- Check60 days agoChange DetectedAdministrative updates were added: a government funding notice about NIH status and a new Revision: v3.4.1 replacing v3.4.0; these updates do not affect study details or enrollment information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.